 Karen Beenken
Concepts (237)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcus aureus | 43 | 2024 | 312 | 4.820 |
Why?
| | Bacterial Proteins | 30 | 2024 | 337 | 3.770 |
Why?
| | Staphylococcal Infections | 26 | 2024 | 272 | 3.290 |
Why?
| | Biofilms | 34 | 2024 | 181 | 3.180 |
Why?
| | Osteomyelitis | 15 | 2024 | 125 | 2.890 |
Why?
| | Trans-Activators | 14 | 2024 | 138 | 2.490 |
Why?
| | Peptide Hydrolases | 12 | 2024 | 63 | 2.330 |
Why?
| | Anti-Bacterial Agents | 19 | 2023 | 796 | 1.940 |
Why?
| | Gene Expression Regulation, Bacterial | 23 | 2024 | 173 | 1.790 |
Why?
| | Chitosan | 7 | 2021 | 42 | 1.230 |
Why?
| | Virulence Factors | 8 | 2024 | 76 | 0.980 |
Why?
| | Disease Models, Animal | 16 | 2024 | 1467 | 0.870 |
Why?
| | Virulence | 15 | 2024 | 160 | 0.850 |
Why?
| | Drug Delivery Systems | 3 | 2021 | 146 | 0.810 |
Why?
| | Mutation | 22 | 2024 | 1318 | 0.800 |
Why?
| | Daptomycin | 6 | 2016 | 29 | 0.800 |
Why?
| | Bone Regeneration | 1 | 2021 | 70 | 0.670 |
Why?
| | Protein Kinases | 3 | 2019 | 72 | 0.660 |
Why?
| | Animals | 37 | 2024 | 13332 | 0.640 |
Why?
| | Mice | 29 | 2024 | 5877 | 0.610 |
Why?
| | Vancomycin | 7 | 2021 | 86 | 0.610 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2018 | 80 | 0.580 |
Why?
| | Prosthesis-Related Infections | 2 | 2017 | 106 | 0.500 |
Why?
| | Catheter-Related Infections | 7 | 2016 | 49 | 0.500 |
Why?
| | Polymethyl Methacrylate | 2 | 2014 | 26 | 0.490 |
Why?
| | Deoxyribonucleases | 3 | 2015 | 23 | 0.480 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2016 | 181 | 0.450 |
Why?
| | Amikacin | 4 | 2018 | 17 | 0.430 |
Why?
| | Rabbits | 5 | 2021 | 371 | 0.420 |
Why?
| | Delayed-Action Preparations | 2 | 2016 | 55 | 0.410 |
Why?
| | Escherichia coli Proteins | 2 | 2005 | 54 | 0.410 |
Why?
| | Xylitol | 1 | 2012 | 7 | 0.390 |
Why?
| | Drug Carriers | 3 | 2017 | 68 | 0.380 |
Why?
| | Coated Materials, Biocompatible | 3 | 2017 | 34 | 0.360 |
Why?
| | Pseudomonas aeruginosa | 5 | 2017 | 76 | 0.350 |
Why?
| | Microbial Sensitivity Tests | 10 | 2023 | 270 | 0.350 |
Why?
| | Bacteremia | 4 | 2017 | 89 | 0.340 |
Why?
| | Epistasis, Genetic | 1 | 2010 | 29 | 0.330 |
Why?
| | Phenotype | 7 | 2021 | 794 | 0.270 |
Why?
| | Metalloendopeptidases | 3 | 2024 | 70 | 0.270 |
Why?
| | Lipoproteins | 2 | 2012 | 41 | 0.260 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2005 | 20 | 0.240 |
Why?
| | Osteoblasts | 3 | 2024 | 473 | 0.240 |
Why?
| | Gram-Negative Bacteria | 1 | 2005 | 34 | 0.240 |
Why?
| | Osteoclasts | 3 | 2024 | 427 | 0.240 |
Why?
| | Escherichia coli | 2 | 2005 | 181 | 0.220 |
Why?
| | Endopeptidases | 2 | 2023 | 63 | 0.220 |
Why?
| | Carrier Proteins | 2 | 2005 | 316 | 0.220 |
Why?
| | Membrane Proteins | 1 | 2005 | 328 | 0.200 |
Why?
| | Polyethylene Glycols | 3 | 2021 | 91 | 0.200 |
Why?
| | RANK Ligand | 1 | 2024 | 187 | 0.200 |
Why?
| | Gene Expression Profiling | 2 | 2006 | 1101 | 0.200 |
Why?
| | RNA, Bacterial | 5 | 2011 | 53 | 0.190 |
Why?
| | Ethylnitrosourea | 1 | 2001 | 9 | 0.180 |
Why?
| | Methylnitrosourea | 1 | 2001 | 10 | 0.180 |
Why?
| | Alkylating Agents | 1 | 2001 | 23 | 0.180 |
Why?
| | Bone Resorption | 1 | 2024 | 302 | 0.180 |
Why?
| | Methyltransferases | 1 | 2001 | 27 | 0.180 |
Why?
| | Proteomics | 3 | 2019 | 325 | 0.180 |
Why?
| | Extracellular Space | 4 | 2021 | 36 | 0.180 |
Why?
| | Gentamicins | 1 | 2021 | 33 | 0.180 |
Why?
| | Durapatite | 1 | 2021 | 23 | 0.170 |
Why?
| | X-Ray Microtomography | 1 | 2021 | 77 | 0.170 |
Why?
| | Biocompatible Materials | 2 | 2021 | 65 | 0.170 |
Why?
| | Tissue Scaffolds | 1 | 2021 | 40 | 0.170 |
Why?
| | Chronic Disease | 2 | 2014 | 585 | 0.170 |
Why?
| | Bacterial Infections | 2 | 2018 | 96 | 0.160 |
Why?
| | Repressor Proteins | 1 | 2021 | 150 | 0.160 |
Why?
| | Gold | 2 | 2018 | 84 | 0.160 |
Why?
| | Bacterial Toxins | 3 | 2020 | 48 | 0.150 |
Why?
| | Osteogenesis | 1 | 2021 | 365 | 0.140 |
Why?
| | Biopolymers | 1 | 2018 | 15 | 0.140 |
Why?
| | Ciprofloxacin | 1 | 2018 | 21 | 0.140 |
Why?
| | RNA, Messenger | 4 | 2011 | 1135 | 0.140 |
Why?
| | Rifampin | 1 | 2018 | 58 | 0.140 |
Why?
| | Coinfection | 1 | 2018 | 41 | 0.140 |
Why?
| | Phosphatidylcholines | 1 | 2017 | 27 | 0.140 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2017 | 11 | 0.140 |
Why?
| | Bone and Bones | 1 | 2021 | 492 | 0.130 |
Why?
| | Proteome | 1 | 2018 | 169 | 0.130 |
Why?
| | Humans | 22 | 2024 | 52114 | 0.130 |
Why?
| | Nanoparticles | 1 | 2018 | 127 | 0.130 |
Why?
| | Recombinases | 1 | 2016 | 10 | 0.120 |
Why?
| | Sigma Factor | 1 | 2016 | 17 | 0.120 |
Why?
| | Peptides, Cyclic | 1 | 2016 | 41 | 0.120 |
Why?
| | Cephalosporins | 1 | 2016 | 37 | 0.120 |
Why?
| | Serine Endopeptidases | 2 | 2014 | 50 | 0.120 |
Why?
| | Prostheses and Implants | 1 | 2015 | 54 | 0.120 |
Why?
| | Genetic Loci | 1 | 2015 | 48 | 0.110 |
Why?
| | Female | 8 | 2024 | 28055 | 0.110 |
Why?
| | Cysteine Endopeptidases | 1 | 2014 | 63 | 0.110 |
Why?
| | Amphotericin B | 1 | 2014 | 104 | 0.110 |
Why?
| | Calcium Sulfate | 1 | 2014 | 7 | 0.110 |
Why?
| | Materials Testing | 1 | 2014 | 55 | 0.110 |
Why?
| | Transcription Factors | 2 | 2014 | 564 | 0.100 |
Why?
| | Plant Extracts | 2 | 2012 | 194 | 0.100 |
Why?
| | Hemolysin Proteins | 2 | 2011 | 15 | 0.100 |
Why?
| | Protease Inhibitors | 2 | 2010 | 59 | 0.100 |
Why?
| | Quercus | 1 | 2012 | 9 | 0.100 |
Why?
| | Carotenoids | 1 | 2012 | 24 | 0.100 |
Why?
| | Magnetite Nanoparticles | 1 | 2012 | 15 | 0.100 |
Why?
| | Debridement | 1 | 2012 | 48 | 0.100 |
Why?
| | Bone Cements | 1 | 2012 | 30 | 0.100 |
Why?
| | Radius | 1 | 2012 | 27 | 0.090 |
Why?
| | RNA Stability | 1 | 2012 | 24 | 0.090 |
Why?
| | Ellagic Acid | 1 | 2012 | 6 | 0.090 |
Why?
| | Antifungal Agents | 1 | 2014 | 346 | 0.090 |
Why?
| | Rosaceae | 1 | 2012 | 9 | 0.090 |
Why?
| | Drug Resistance, Multiple, Bacterial | 2 | 2016 | 57 | 0.090 |
Why?
| | Surgical Wound Infection | 1 | 2012 | 117 | 0.090 |
Why?
| | Radiopharmaceuticals | 1 | 2012 | 199 | 0.090 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2012 | 181 | 0.090 |
Why?
| | Ribonuclease P | 1 | 2011 | 3 | 0.090 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2011 | 23 | 0.090 |
Why?
| | RNA-Binding Proteins | 1 | 2012 | 134 | 0.090 |
Why?
| | Polysaccharides, Bacterial | 1 | 2010 | 12 | 0.080 |
Why?
| | Adhesins, Bacterial | 3 | 2012 | 27 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2011 | 106 | 0.080 |
Why?
| | Mice, Inbred C57BL | 3 | 2020 | 1872 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 1368 | 0.070 |
Why?
| | Male | 6 | 2014 | 26652 | 0.070 |
Why?
| | Adaptation, Physiological | 2 | 2006 | 110 | 0.070 |
Why?
| | Models, Biological | 2 | 2011 | 731 | 0.070 |
Why?
| | Operon | 2 | 2016 | 24 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2018 | 335 | 0.060 |
Why?
| | Membrane Fusion Proteins | 1 | 2005 | 1 | 0.060 |
Why?
| | Biological Transport, Active | 1 | 2005 | 29 | 0.060 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2005 | 17 | 0.060 |
Why?
| | Catheters | 2 | 2016 | 34 | 0.060 |
Why?
| | Membrane Transport Proteins | 1 | 2005 | 46 | 0.060 |
Why?
| | Brain | 1 | 2013 | 1311 | 0.060 |
Why?
| | Arthritis, Infectious | 2 | 2003 | 43 | 0.060 |
Why?
| | Protein Conformation | 1 | 2005 | 177 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2003 | 373 | 0.060 |
Why?
| | Plankton | 1 | 2004 | 6 | 0.060 |
Why?
| | Anaerobiosis | 1 | 2004 | 20 | 0.050 |
Why?
| | Models, Molecular | 1 | 2005 | 351 | 0.050 |
Why?
| | Genes, Bacterial | 1 | 2004 | 51 | 0.050 |
Why?
| | Colony Count, Microbial | 1 | 2004 | 59 | 0.050 |
Why?
| | Methicillin | 1 | 2024 | 10 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2004 | 177 | 0.050 |
Why?
| | Mammals | 1 | 2024 | 59 | 0.050 |
Why?
| | Femur | 1 | 2024 | 132 | 0.050 |
Why?
| | Catheterization | 1 | 2004 | 95 | 0.050 |
Why?
| | Mice, Inbred BALB C | 1 | 2004 | 307 | 0.050 |
Why?
| | Down-Regulation | 1 | 2004 | 343 | 0.050 |
Why?
| | Up-Regulation | 1 | 2004 | 459 | 0.050 |
Why?
| | Musculoskeletal Diseases | 1 | 2003 | 51 | 0.050 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 232 | 0.050 |
Why?
| | Alkylation | 1 | 2001 | 10 | 0.050 |
Why?
| | Mutagenesis | 1 | 2001 | 60 | 0.040 |
Why?
| | Staphylococcus | 1 | 2001 | 32 | 0.040 |
Why?
| | Research Design | 1 | 2023 | 367 | 0.040 |
Why?
| | Mannitol | 1 | 2021 | 15 | 0.040 |
Why?
| | Titanium | 1 | 2021 | 36 | 0.040 |
Why?
| | DNA Transposable Elements | 1 | 2021 | 107 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 96 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2001 | 460 | 0.040 |
Why?
| | Gene Expression | 1 | 2001 | 618 | 0.040 |
Why?
| | Sepsis | 1 | 2021 | 229 | 0.040 |
Why?
| | Genotype | 1 | 2020 | 563 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 249 | 0.030 |
Why?
| | Drug Combinations | 1 | 2017 | 134 | 0.030 |
Why?
| | Teicoplanin | 1 | 2016 | 4 | 0.030 |
Why?
| | Glycopeptides | 1 | 2016 | 12 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2018 | 554 | 0.030 |
Why?
| | Aminoglycosides | 1 | 2016 | 20 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2016 | 141 | 0.030 |
Why?
| | Freeze Drying | 1 | 2016 | 6 | 0.030 |
Why?
| | Drug Compounding | 1 | 2016 | 26 | 0.030 |
Why?
| | Polytetrafluoroethylene | 1 | 2016 | 33 | 0.030 |
Why?
| | Acetates | 1 | 2016 | 51 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2016 | 76 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2015 | 43 | 0.030 |
Why?
| | Porifera | 1 | 2014 | 7 | 0.030 |
Why?
| | Musculoskeletal System | 1 | 2014 | 16 | 0.030 |
Why?
| | Point-of-Care Systems | 1 | 2015 | 65 | 0.030 |
Why?
| | Cerebral Ventricles | 1 | 2013 | 23 | 0.030 |
Why?
| | Plant Stems | 1 | 2012 | 13 | 0.020 |
Why?
| | Animals, Outbred Strains | 1 | 2012 | 12 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2012 | 5 | 0.020 |
Why?
| | Photochemical Processes | 1 | 2012 | 5 | 0.020 |
Why?
| | Color | 1 | 2012 | 15 | 0.020 |
Why?
| | Plant Leaves | 1 | 2012 | 40 | 0.020 |
Why?
| | Skin | 1 | 2016 | 418 | 0.020 |
Why?
| | Photoacoustic Techniques | 1 | 2012 | 24 | 0.020 |
Why?
| | Molecular Imaging | 1 | 2012 | 28 | 0.020 |
Why?
| | Light | 1 | 2012 | 51 | 0.020 |
Why?
| | Complementary Therapies | 1 | 2012 | 23 | 0.020 |
Why?
| | Lasers | 1 | 2012 | 65 | 0.020 |
Why?
| | Mice, Nude | 1 | 2012 | 231 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2012 | 48 | 0.020 |
Why?
| | Antibodies | 1 | 2012 | 148 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2012 | 71 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2012 | 17 | 0.020 |
Why?
| | Biological Assay | 1 | 2012 | 46 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2012 | 75 | 0.020 |
Why?
| | Fruit | 1 | 2012 | 129 | 0.020 |
Why?
| | Glycosylation | 1 | 2012 | 103 | 0.020 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 61 | 0.020 |
Why?
| | Hot Temperature | 1 | 2012 | 199 | 0.020 |
Why?
| | Cell Death | 1 | 2012 | 169 | 0.020 |
Why?
| | Hep G2 Cells | 1 | 2011 | 40 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 580 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 588 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2012 | 239 | 0.020 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 66 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2012 | 293 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2012 | 297 | 0.020 |
Why?
| | Protein Binding | 1 | 2012 | 665 | 0.020 |
Why?
| | Phenols | 1 | 2011 | 92 | 0.020 |
Why?
| | Genetic Variation | 1 | 2011 | 224 | 0.020 |
Why?
| | Inflammation | 1 | 2013 | 641 | 0.020 |
Why?
| | Cell Line | 1 | 2012 | 1018 | 0.020 |
Why?
| | Acetoin | 1 | 2008 | 2 | 0.020 |
Why?
| | Micrococcal Nuclease | 1 | 2008 | 7 | 0.020 |
Why?
| | Butylene Glycols | 1 | 2008 | 14 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 2008 | 43 | 0.020 |
Why?
| | Regulon | 1 | 2006 | 6 | 0.020 |
Why?
| | Cell Survival | 1 | 2008 | 596 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2013 | 1071 | 0.020 |
Why?
| | Rats | 1 | 2012 | 3146 | 0.020 |
Why?
| | Gene Deletion | 1 | 2006 | 274 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 411 | 0.010 |
Why?
| | RNA, Antisense | 1 | 2002 | 6 | 0.010 |
Why?
| | Lipase | 1 | 2002 | 11 | 0.010 |
Why?
| | Hemolysis | 1 | 2002 | 28 | 0.010 |
Why?
| | Fibronectins | 1 | 2002 | 36 | 0.010 |
Why?
| | Genes, rRNA | 1 | 2001 | 7 | 0.010 |
Why?
| | Blood | 1 | 2001 | 25 | 0.010 |
Why?
| | Culture Media | 1 | 2001 | 98 | 0.010 |
Why?
| | Child | 1 | 2013 | 7147 | 0.010 |
Why?
| | DNA Primers | 1 | 2001 | 204 | 0.010 |
Why?
| | Collagen | 1 | 2002 | 215 | 0.010 |
Why?
| | Incidence | 1 | 2003 | 1070 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2003 | 1035 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2001 | 871 | 0.010 |
Why?
|
|
Beenken's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|